

Louisiana Department of Wildlife and Fisheries
 L.S.U. Dental School
 L.S.U. Medical Center
 Lubriport Laboratories, Inc.
 Lucas Western, Inc.
 Marathon Oil Co./Marathon Petroleum Co.
 Master Well Works, Inc.
 Melamine Chemicals, Inc.
 Merrill Bean Chevrolet
 Metricor (Corning, Inc.)
 Metro Environmental Laboratory
 Metro Transit Power Distribution
 Metro West Point Treatment Plant
 Metropolitan Water District of Salt Lake City
 Missouri Southern State College
 Mountain States Analytical
 Multichemical Products, Inc.
 Natchez Boat Store (Canal Barge Company, Inc.)
 New Orleans Spice Co. Labs
 Newark Unified School District
 North Seattle Community College
 Northeast Louisiana University
 NPI (Agridyne)
 Nuclear Sources & Services
 Occidental Chemical Corporation (OxyChem)
 Oregon Regional Primate Center
 Our Lady of the Lake Medical Center
 Oxwell, Inc.
 Packard Instrument Company
 PATCO (Port Arthur Towing Company)
 Pepperidge Farm, Inc.
 Pepsi Cola Bottling of Ogden
 Peterson/Puritan, Inc. (CCL Custom Manufacturing)
 Petrofunds, Inc.
 Petroleum Stripping, Inc.
 Phillips 66 Company (Phillips Petroleum Company)
 Phillips Philtex (Phillips Petroleum Company)
 Physio-Control Corporation (Eli Lilly & Company)
 Placid Refining Company
 Plantation Pipe Line Company
 Plaza Point Investment
 Portland State University
 Providence Medical Center Hospital (Sisters of Providence)
 Puget Sound Power & Light Company
 Rayne City Hall
 Rent-It Center, Inc.
 Rexene Products Co./El Paso Products Company (Rexene Corporation)
 Safelite Industries (Safelite Glass Corp.)
 Salt Lake City
 Sears, Roebuck and Co.
 Sherwin-Williams Company
 Smith Flooring, Inc.
 South Seattle Community College
 Southern Research Institute
 Southern University, Baton Rouge, and Southern University, New Orleans
 Southwall Technologies
 Spell Brothers Trucking

St. Tammany Parish Hospital
 Sterling Drug Co. (Sterling Winthrop, Inc.)
 Tenneco Oil Company
 Tennessee Gas Pipeline (Tenneco Energy)
 Texas City Refining, Inc.
 Texas Eastern Transmission Corporation
 Texas Gas Transmission Corporation
 Texas Southern University
 Texas Tech University
 The Woodlands Technology Center (Pennzoil Company)
 Tidewater Marine, Inc.
 Transco/Transcontinental Gas Pipe Line Corporation
 Trumbull Asphalt (Owens-Corning)
 U.S. Post Office
 University of Alabama
 University of Arkansas
 University of California, Riverside
 University of Houston
 University of South Alabama
 University of Southern Mississippi
 University of Texas
 University of Utah
 Utah Correctional Industries
 Utah Correctional Institute
 Utah State University
 Varian Associates, Inc.
 Virginia Mason Hospital (Virginia Mason Medical Center)
 Washington State Department of Transportation
 Welchem, Inc. (Amoco Corporation)
 Westlake Polymers Corporation
 Weyerhaeuser Technology Center
 Wil-Cor, Inc.
 Wilson Supply Co./Wilson Industries, Inc.
 Xavier University of Louisiana

Dated: August 22, 1996.
 Jane N. Saginaw,
Regional Administrator.
 [FR Doc. 96-22384 Filed 8-30-96; 8:45 am]
 BILLING CODE 6560-50-P

EXPORT-IMPORT BANK OF THE UNITED STATES

Notice of Open Special Meeting of the Advisory Committee of the Export-Import Bank of the United States

SUMMARY: The Advisory Committee was established by Pub. L. 98-181, November 30, 1983, to advise the Export-Import Bank on its programs and to provide comments for inclusion in the reports of the Export-Import Bank to the United States Congress.

Time and Place: Thursday, September 26, 1996, at 9:30 a.m. to 12:00 noon. The meeting will be held at EX-IM Bank in Room 1143, 811 Vermont Avenue, N.W., Washington, D.C. 20571.

Agenda: The meeting agenda will include a discussion of the following: Reports from

the 3 Working Groups, Discussion on GAO Ideas, Next Steps and other topics.

Public Participation: The meeting will be open to public participation; and the last 10 minutes will be set aside for oral questions or comments. Members of the public may also file written statement(s) before or after the meeting. In order to permit the Export-Import Bank to arrange suitable accommodations, members of the public who plan to attend the meeting should notify Joyce Herron, Room 1215, 811 Vermont Avenue, N.W., Washington, D.C. 20571, (202) 565-3503, not later than September 23, 1996. If any person wishes auxiliary aids (such as a sign language interpreter) or other special accommodations, please contact, prior to September 26, 1996, Joyce Herron, Room 1215, 811 Vermont Avenue, N.W., Washington, DC 20571, Voice: (202) 565-3955 or TDD: (303) 565-3377.

FURTHER INFORMATION: For further information, contact Joyce Herron, Room 1215, 811 Vermont Avenue, N.W., Washington, D.C. 20571, (202) 565-3503.

Kenneth Hansen,

General Counsel.

[FR Doc. 96-22268 Filed 8-30-96; 8:45 am]

BILLING CODE 6690-01-M

FEDERAL MARITIME COMMISSION

Notice of Agreement(s) Filed

The Federal Maritime Commission hereby gives notice of the filing of the following agreement(s) pursuant to section 5 of the Shipping Act of 1984.

Interested parties may inspect and obtain a copy of each agreement at the Washington, D.C. Office of the Federal Maritime Commission, 800 North Capitol Street, N.W., 9th Floor. Interested parties may submit comments on each agreement to the Secretary, Federal Maritime Commission, Washington, D.C. 20573, within 10 days after the date of the Federal Register in which this notice appears. The requirements for comments are found in section 572.603 of Title 46 of the Code of Federal Regulations. Interested persons should consult this section before communicating with the Commission regarding a pending agreement.

Agreement No.: 232-010786-008.

Title: Contship Containerlines Limited/Italia di Navigazione SPA Space Charter and Sailing Agreement.

Parties: Contship Containerlines Limited Italia di Navigazione S.P.A.

Synopsis: The proposed amendment revises Article 5.7 by deleting the Agreement's authority to agree upon rates, rules, regulations and other tariff items. It also deletes Article 5.8.

Agreement No.: 232-011553.

Title: CSAV/Nacional Space Charter Agreement.

Parties: Compania Sud Americana de Vapores ("CSAV") Companhia Maritima Nacional ("Nacional").

Synopsis: The proposed Agreement permits Nacional to charter space on CSAV's vessels and coordinate sailings in the trade between East Coast ports in South America and U.S. Atlantic Coast ports and points.

Dated: August 28, 1996.

By Order of the Federal Maritime Commission.

Joseph C. Polking,

Secretary.

[FR Doc. 96-22355 Filed 8-30-96; 8:45 am]

BILLING CODE 6730-01-M

FEDERAL RESERVE SYSTEM

Change in Bank Control Notices; Acquisitions of Shares of Banks or Bank Holding Companies

The notificants listed below have applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notices are available for immediate inspection at the Federal Reserve Bank indicated. Once the notices have been accepted for processing, they will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than September 17, 1996.

A. Federal Reserve Bank of Minneapolis (Karen L. Grandstrand, Vice President) 250 Marquette Avenue, Minneapolis, Minnesota 55480:

1. *Raye Plahn Revocable Trust* (Trustee is Ms. Raye Plahn), both of Shell Lake, Wisconsin; to retain a total of 10.52 percent of the voting shares of Shell Lake Bancorp, Inc., Shell Lake, Wisconsin, and thereby indirectly acquire Shell Lake State Bank, Shell Lake, Wisconsin.

B. Federal Reserve Bank of Dallas (Genie D. Short, Vice President) 2200 North Pearl Street, Dallas, Texas 75201-2272:

1. *Joe Dan Coe*, Winnsboro, Texas; to retain a total of 14.09 percent of the voting shares of Franklin National Bankshares, Inc., Mt. Vernon, Texas, and thereby indirectly acquire Franklin National Bank, Mt. Vernon, Texas.

Board of Governors of the Federal Reserve System, August 27, 1996.

William W. Wiles

Secretary of the Board.

[FR Doc. 96-22281 Filed 8-30-96; 8:45 am]

BILLING CODE 6210-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Advisory Committee to the Director, Centers for Disease Control and Prevention: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

Name: Advisory Committee to the Director, CDC.

Time and Date: 8:30 a.m.-3 p.m., September 19, 1996.

Place: CDC, Auditorium A, 1600 Clifton Road, NE, Atlanta, Georgia 30333.

Status: Open to the public, limited only by the space available.

Purpose: This committee advises the Director, CDC, on policy issues and broad strategies that will enable CDC, the Nation's prevention agency, to fulfill its mission of promoting health and quality of life by preventing and controlling disease, injury, and disability. The Committee recommends ways to incorporate prevention activities more fully into health care. It also provides guidance to help CDC work more effectively with its various constituents, in both the private and public sectors, to make prevention a practical reality.

Matters to be Discussed: Agenda items will include updates from CDC Director, David Satcher, M.D., Ph.D., followed by committee discussion on strategic thinking about the future of CDC and public health, and on lessons from the Los Angeles measles vaccine study.

Agenda items are subject to change as priorities dictate.

Contact Person For More Information: Linda Kay McGowan, Acting Executive Secretary, Advisory Committee to the Director, CDC, 1600 Clifton Road, NE, M/S D-24, Atlanta, Georgia 30333, telephone 404/639-7080.

Dated: August 27, 1996.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 96-22333 Filed 8-30-96; 8:45 am]

BILLING CODE 4163-18-M

Food and Drug Administration

[Docket No. 96E-0102]

Determination of Regulatory Review Period for Purposes of Patent Extension; CEDAX® Capsules

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) has determined the regulatory review period for CEDAX® capsules and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.

ADDRESSES: Written comments and petitions should be directed to the Dockets Management Branch (HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Brian J. Malkin, Office of Health Affairs (HFY-20), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-1382.

SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term Restoration Act of 1984 (Pub. L. 98-417) and the Generic Animal Drug and Patent Term Restoration Act (Pub. L. 100-670) generally provide that a patent may be extended for a period of up to 5 years so long as the patented item (human drug product, animal drug product, medical device, food additive, or color additive) was subject to regulatory review by FDA before the item was marketed. Under these acts, a product's regulatory review period forms the basis for determining the amount of extension an applicant may receive.

A regulatory review period consists of two periods of time: A testing phase and an approval phase. For human drug products, the testing phase begins when the exemption to permit the clinical investigations of the drug becomes effective and runs until the approval phase begins. The approval phase starts with the initial submission of an application to market the human drug product and continues until FDA grants permission to market the drug product. Although only a portion of a regulatory review period may count toward the actual amount of extension that the Commissioner of Patents and Trademarks may award (for example, half the testing phase must be